• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

I 型干扰素与 SARS-CoV-2:从细胞到机体。

Type I interferons and SARS-CoV-2: from cells to organisms.

机构信息

Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France; University of Paris, Imagine Institute, Paris, France; St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA; Department of Pediatrics, Necker Hospital for Sick Children, AP-HP, Paris, France.

Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France; University of Paris, Imagine Institute, Paris, France; St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA.

出版信息

Curr Opin Immunol. 2022 Feb;74:172-182. doi: 10.1016/j.coi.2022.01.003. Epub 2022 Jan 25.

DOI:10.1016/j.coi.2022.01.003
PMID:35149239
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8786610/
Abstract

Type I interferons (IFNs) have broad and potent antiviral activity. We review the interplay between type I IFNs and SARS-CoV-2. Human cells infected with SARS-CoV-2 in vitro produce low levels of type I IFNs, and SARS-CoV-2 proteins can inhibit various steps in type I IFN production and response. Exogenous type I IFNs inhibit viral growth in vitro. In various animal species infected in vivo, type I IFN deficiencies underlie higher viral loads and more severe disease than in control animals. The early administration of exogenous type I IFNs improves infection control. In humans, inborn errors of, and auto-antibodies against type I IFNs underlie life-threatening COVID-19 pneumonia. Overall, type I IFNs are essential for host defense against SARS-CoV-2 in individual cells and whole organisms.

摘要

I 型干扰素(IFNs)具有广泛而强大的抗病毒活性。我们回顾了 I 型干扰素与 SARS-CoV-2 之间的相互作用。体外感染 SARS-CoV-2 的人细胞产生低水平的 I 型干扰素,SARS-CoV-2 蛋白可以抑制 I 型 IFN 产生和反应的各个步骤。外源性 I 型干扰素可抑制体外病毒生长。在体内感染的各种动物物种中,与对照动物相比,I 型 IFN 缺陷导致更高的病毒载量和更严重的疾病。早期给予外源性 I 型干扰素可改善感染控制。在人类中,I 型干扰素的先天缺陷和自身抗体是导致危及生命的 COVID-19 肺炎的基础。总的来说,I 型干扰素是宿主抵抗 SARS-CoV-2 的个体细胞和整个机体防御所必需的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e544/8786610/893ed72c54f4/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e544/8786610/a429847252a5/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e544/8786610/893ed72c54f4/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e544/8786610/a429847252a5/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e544/8786610/893ed72c54f4/gr2_lrg.jpg

相似文献

1
Type I interferons and SARS-CoV-2: from cells to organisms.I 型干扰素与 SARS-CoV-2:从细胞到机体。
Curr Opin Immunol. 2022 Feb;74:172-182. doi: 10.1016/j.coi.2022.01.003. Epub 2022 Jan 25.
2
Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.I型、II型和III型干扰素的抗病毒活性可抵消ACE2的诱导性并限制新型冠状病毒。
mBio. 2020 Sep 10;11(5):e01928-20. doi: 10.1128/mBio.01928-20.
3
Type I and III interferon responses in SARS-CoV-2 infection.SARS-CoV-2 感染中的 I 型和 III 型干扰素反应。
Exp Mol Med. 2021 May;53(5):750-760. doi: 10.1038/s12276-021-00592-0. Epub 2021 May 6.
4
Differential interferon-α subtype induced immune signatures are associated with suppression of SARS-CoV-2 infection.不同亚型干扰素-α诱导的免疫特征与抑制 SARS-CoV-2 感染有关。
Proc Natl Acad Sci U S A. 2022 Feb 22;119(8). doi: 10.1073/pnas.2111600119.
5
The RNA sensor MDA5 detects SARS-CoV-2 infection.RNA 传感器 MDA5 可检测 SARS-CoV-2 感染。
Sci Rep. 2021 Jul 1;11(1):13638. doi: 10.1038/s41598-021-92940-3.
6
Plasma Exchange to Rescue Patients with Autoantibodies Against Type I Interferons and Life-Threatening COVID-19 Pneumonia.血浆置换挽救抗 I 型干扰素自身抗体阳性和危及生命的 COVID-19 肺炎患者。
J Clin Immunol. 2021 Apr;41(3):536-544. doi: 10.1007/s10875-021-00994-9. Epub 2021 Feb 22.
7
Pre-existing Autoantibodies Neutralizing High Concentrations of Type I Interferons in Almost 10% of COVID-19 Patients Admitted to Intensive Care in Barcelona.巴塞罗那 ICU 收治的 COVID-19 患者中,近 10% 患者预先存在中和高浓度 I 型干扰素的自身抗体。
J Clin Immunol. 2021 Nov;41(8):1733-1744. doi: 10.1007/s10875-021-01136-x. Epub 2021 Sep 27.
8
Protective Potentials of Type III Interferons in COVID-19 Patients: Lessons from Differential Properties of Type I- and III Interferons.III型干扰素在新冠患者中的保护作用:从I型和III型干扰素的差异特性中汲取的经验教训
Viral Immunol. 2021 Jun;34(5):307-320. doi: 10.1089/vim.2020.0076. Epub 2020 Nov 4.
9
Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures.Ⅰ型和Ⅲ型干扰素限制 SARS-CoV-2 感染人呼吸道上皮细胞。
J Virol. 2020 Sep 15;94(19). doi: 10.1128/JVI.00985-20.
10
Type I IFNs: A Blessing in Disguise or Partner in Crime in MERS-CoV-, SARS-CoV-, and SARS-CoV-2-Induced Pathology and Potential Use of Type I IFNs in Synergism with IFN- as a Novel Antiviral Approach Against COVID-19.I 型干扰素:在中东呼吸综合征冠状病毒、严重急性呼吸综合征冠状病毒和严重急性呼吸综合征冠状病毒 2 诱导的病理中的伪装祝福或共犯,以及 I 型干扰素与 IFN-协同作用作为针对 COVID-19 的新型抗病毒方法的潜在用途。
Viral Immunol. 2021 Jun;34(5):321-329. doi: 10.1089/vim.2020.0085. Epub 2020 Nov 11.

引用本文的文献

1
Evolutionary divergence of induced versus constitutive antiviral gene expression levels between primates and rodents.灵长类动物和啮齿动物之间诱导型与组成型抗病毒基因表达水平的进化差异。
PLoS Comput Biol. 2025 Jun 24;21(6):e1013165. doi: 10.1371/journal.pcbi.1013165. eCollection 2025 Jun.
2
Nerve- and airway-associated interstitial macrophages mitigate SARS-CoV-2 pathogenesis via type I interferon signaling.神经和气道相关间质巨噬细胞通过I型干扰素信号传导减轻SARS-CoV-2发病机制。
Immunity. 2025 May 13;58(5):1327-1342.e5. doi: 10.1016/j.immuni.2025.04.001. Epub 2025 Apr 25.
3
Antibodies to the RBD of SARS-CoV-2 spike mediate productive infection of primary human macrophages.

本文引用的文献

1
Interferon resistance of emerging SARS-CoV-2 variants.新兴 SARS-CoV-2 变异株的干扰素耐药性。
Proc Natl Acad Sci U S A. 2022 Aug 9;119(32):e2203760119. doi: 10.1073/pnas.2203760119. Epub 2022 Jul 22.
2
Autoantibodies Neutralizing Type I Interferons in 20% of COVID-19 Deaths in a French Hospital.法国一医院 20%的新冠肺炎死亡患者存在中和 I 型干扰素的自身抗体。
J Clin Immunol. 2022 Apr;42(3):459-470. doi: 10.1007/s10875-021-01203-3. Epub 2022 Jan 27.
3
Delayed induction of type I and III interferons mediates nasal epithelial cell permissiveness to SARS-CoV-2.
针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白受体结合域(RBD)的抗体介导原代人巨噬细胞的有效感染。
Nat Commun. 2024 Dec 30;15(1):10764. doi: 10.1038/s41467-024-54458-w.
4
A common form of dominant human IFNAR1 deficiency impairs IFN-α and -ω but not IFN-β-dependent immunity.一种常见的显性人类干扰素α/β受体1(IFNAR1)缺陷形式会损害IFN-α和-ω介导的免疫,但不影响IFN-β依赖的免疫。
J Exp Med. 2025 Feb 3;222(2). doi: 10.1084/jem.20241413. Epub 2024 Dec 16.
5
A genome-wide arrayed CRISPR screen identifies PLSCR1 as an intrinsic barrier to SARS-CoV-2 entry that recent virus variants have evolved to resist.全基因组 CRISPR 敲除筛选发现 PLCSR1 是新冠病毒进入细胞的内在屏障,近期的病毒变异体已进化出抵抗该屏障的能力。
PLoS Biol. 2024 Sep 24;22(9):e3002767. doi: 10.1371/journal.pbio.3002767. eCollection 2024 Sep.
6
Exploring the potency of polyphenol-rich blend from var. sevast., , and : Promising anti-inflammatory, antioxidant, and antiviral properties.探索来自var. sevast.、、和的富含多酚混合物的效力:具有有前景的抗炎、抗氧化和抗病毒特性。
Heliyon. 2024 Aug 2;10(15):e35630. doi: 10.1016/j.heliyon.2024.e35630. eCollection 2024 Aug 15.
7
COVID-19 Pneumonia and Cytokine Storm Syndrome.新型冠状病毒肺炎及细胞因子风暴综合征
Adv Exp Med Biol. 2024;1448:307-319. doi: 10.1007/978-3-031-59815-9_22.
8
Pathway-Based Mendelian Randomization for Pre-Infection IL-6 Levels Highlights Its Role in Coronavirus Disease.基于通路的孟德尔随机化分析提示感染前白细胞介素 6 水平在冠状病毒病中的作用
Genes (Basel). 2024 Jul 6;15(7):889. doi: 10.3390/genes15070889.
9
The Microbe, the Infection Enigma, and the Host.微生物、感染之谜与宿主
Annu Rev Microbiol. 2024 Nov;78(1):103-124. doi: 10.1146/annurev-micro-092123-022855. Epub 2024 Nov 7.
10
Primary nasal influenza infection rewires tissue-scale memory response dynamics.原发性鼻腔流感感染重编组织尺度记忆反应动力学。
Immunity. 2024 Aug 13;57(8):1955-1974.e8. doi: 10.1016/j.immuni.2024.06.005. Epub 2024 Jul 3.
I 型和 III 型干扰素的延迟诱导介导了鼻腔上皮细胞对 SARS-CoV-2 的易感性。
Nat Commun. 2021 Dec 7;12(1):7092. doi: 10.1038/s41467-021-27318-0.
4
Impaired innate antiviral defenses in COVID-19: Causes, consequences and therapeutic opportunities.COVID-19 中先天抗病毒防御功能受损:原因、后果和治疗机会。
Semin Immunol. 2021 Jun;55:101522. doi: 10.1016/j.smim.2021.101522. Epub 2021 Nov 9.
5
Monoclonal antibody-mediated neutralization of SARS-CoV-2 in an IRF9-deficient child.IRF9 缺陷患儿中,单克隆抗体介导的 SARS-CoV-2 中和作用。
Proc Natl Acad Sci U S A. 2021 Nov 9;118(45). doi: 10.1073/pnas.2114390118.
6
The type I interferonopathies: 10 years on.Ⅰ型干扰素病:10 年进展。
Nat Rev Immunol. 2022 Aug;22(8):471-483. doi: 10.1038/s41577-021-00633-9. Epub 2021 Oct 20.
7
Type I Interferon Induction and Exhaustion during Viral Infection: Plasmacytoid Dendritic Cells and Emerging COVID-19 Findings.病毒感染期间的 I 型干扰素诱导和耗竭:浆细胞样树突状细胞和新兴的 COVID-19 研究结果。
Viruses. 2021 Sep 15;13(9):1839. doi: 10.3390/v13091839.
8
TLR3 and TLR7 RNA Sensor Activation during SARS-CoV-2 Infection.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染期间Toll样受体3(TLR3)和Toll样受体7(TLR7)RNA传感器的激活
Microorganisms. 2021 Aug 26;9(9):1820. doi: 10.3390/microorganisms9091820.
9
Type I Interferons in COVID-19 Pathogenesis.1型干扰素在新冠病毒疾病发病机制中的作用
Biology (Basel). 2021 Aug 26;10(9):829. doi: 10.3390/biology10090829.
10
Pre-existing Autoantibodies Neutralizing High Concentrations of Type I Interferons in Almost 10% of COVID-19 Patients Admitted to Intensive Care in Barcelona.巴塞罗那 ICU 收治的 COVID-19 患者中,近 10% 患者预先存在中和高浓度 I 型干扰素的自身抗体。
J Clin Immunol. 2021 Nov;41(8):1733-1744. doi: 10.1007/s10875-021-01136-x. Epub 2021 Sep 27.